Veru Inc. (VERU)

CIK 0000863894 · Healthcare · Biotechnology

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest Q2-2026 8-K (2026-05-13) · 99.1
Q1-2026 8-K (2026-02-11) · 99.1
Latest FY-2025 8-K (2025-12-17) · 99.1
Q3-2025 8-K (2025-08-12) · 99.1
Q2-2025 8-K (2025-05-08) · 99.1
Q1-2025 8-K (2025-02-13) · 99.1
FY-2024 —
Q3-2024 8-K (2024-08-08) · 99.1
Q2-2024 8-K (2024-05-08) · 99.1
Q1-2024 8-K (2024-02-08) · 99.1
FY-2023
FY-2023 —
Q3-2023
Q3-2023 8-K (2023-08-10) · 99.1

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Document and Entity Information
Statements
Consolidated Balance Sheets
Unaudited Condensed Consolidated Balance Sheets
—
Consolidated Balance Sheets (P)
Unaudited Condensed Consolidated Balance Sheets (P)
—
Consolidated Statements of Operations
Unaudited Condensed Consolidated Statements of Operations
—
Consolidated Statements of Stockholders' Equity
Unaudited Condensed Consolidated Statements of Stockholders' Equity
—
Consolidated Statements of Cash Flows
Unaudited Condensed Consolidated Statements of Cash Flows
—
Notes
Accounts Receivable and Concentration of Credit Risk
Award Timing Disclosure
—
Balance Sheet Information
—
Basis of Presentation
—
Contingent Liabilities
Cybersecurity Risk Management and Strategy Disclosure
—
Debt
Employee Benefit Plans
—
Fair Value Measurements
Going Concern
—
Goodwill
—
Income Taxes
Insider Trading Arrangements
Insider Trading Policies and Procedures
—
Intangible Assets and Goodwill
Inventories
—
Leases
Liquidity
—
Loss Per Share
—
Nature of Business and Significant Accounting Policies
—
Net Income (loss) Per Share
—
Net Loss Per Share
—
Note 1
Note 10
Note 10 -share-based Compensation
—
Note 11
Note 12
Note 13
Note 14
Note 15
Note 16
Note 17
—
Note 18
—
Note 2
Note 3
Note 4
Note 5
Note 6
Note 7
Note 8
Note 9
Property and Equipment
—
Revenue From Contracts With Customers
Sale of Entadfi
—
Sale of Entadfi Assets
—
Share-based Compensation
Stockholders' Equity
Subsequent Events
—